AC
INZY

Aaron Cowen’s Inozyme Pharma INZY Stock Holding History

Aaron Cowen’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,013,216
Closed -$4.14M – 94
2022
Q1 		$4.14M Hold
1,013,216
– – 0.13% 65
2021
Q4 		$6.91M Buy
1,013,216
+26,816
+3% +$232K 0.13% 67
2021
Q3 		$11.4M Buy
986,400
+621,228
+170% +$9.69M 0.19% 64
2021
Q2 		$6.22M Buy
365,172
+23,745
+7% +$413K 0.09% 87
2021
Q1 		$6.76M Buy
341,427
+127,116
+59% +$2.8M 0.1% 82
2020
Q4 		$4.42M Buy
+214,311
New +$5.11M 0.06% 81

Other funds holding INZY

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aaron Cowen's INZY Position: Q2 2022 in Review

Aaron Cowen sold out of Inozyme Pharma (INZY) in Q2 2022, closing a stake of 1,013,216 shares — an estimated $4.14M sold.

Aaron Cowen first reported a position in INZY in Q4 2020 and held it in 6 quarters. The position peaked at $11.4M in Q3 2021. 47 funds tracked by Wall St. Rank hold INZY as of Q2 2022.

  • Aaron Cowen reported no remaining Inozyme Pharma position as of Q2 2022 after selling out during the quarter.
  • Aaron Cowen sold 1,013,216 Inozyme Pharma shares in Q2 2022, an estimated $4.14M.
  • Aaron Cowen first reported a position in Inozyme Pharma in Q4 2020 and held it in 6 quarters.
  • Aaron Cowen's Inozyme Pharma position peaked at $11.4M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.